

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Max Healthcare and Tata Institute for Genetics and Society sign MoU to advance healthcare through genomics and research

03 November 2025 | News

To address some of the most pressing healthcare challenges



Max Healthcare, one of the largest private sector healthcare services companies in India, and Tata Institute for Genetics and Society (TIGS), a leading genomics research institute, have announced the signing of a Memorandum of Understanding (MoU).

This landmark agreement will establish a collaborative platform for pioneering research, training, and knowledge exchange in the fields of genetics and healthcare, with the shared goal of improving patient outcomes and advancing clinical science.

The MoU was signed in a ceremony attended by senior representatives from both the organisations. This partnership will focus on leveraging cutting-edge genomic research to address some of the most pressing healthcare challenges. Key areas of collaboration will include joint research projects in rare genetic diseases, a dedicated focus on neonatal care through genomic insights, and the development of personalized medicine based on genetic profiling.

This collaboration will also facilitate the exchange of knowledge and expertise between scientists, clinicians, and researchers from both institutions through joint conferences, workshops, and training programmes. By combining Max Healthcare's extensive clinical expertise and patient data with TIGS's advanced genomics research capabilities, the partnership aims to accelerate the translation of research findings into clinical practice.

The collaboration marks a significant step forward in advancing the role of genetics in haematology and neonatal care. By combining expertise in these fields, the partnership aims to deepen understanding of the genetic basis of blood disorders, cancers, and critical neonatal conditions. This will not only enable more precise diagnosis and personalized treatment strategies but also improve early identification of genetic risk factors in newborns. Together, these efforts have the potential to transform patient care and outcomes, ushering in a new era of genomic medicine.